OneSource Specialty Pharma Limited has disclosed to stock exchanges that it received an Environmental, Social, and Governance (ESG) score of 65.7 from SES ESG Research Private Limited. The pharmaceutical company made this intimation on February 12, 2026, in compliance with SEBI listing regulations.

ESG Rating Details

The ESG assessment was conducted independently by SES ESG Research Private Limited based on publicly available data pertaining to the company's FY 2024-25 performance. The rating report was received by OneSource Specialty Pharma on February 11, 2026.

Regulatory Compliance

The company emphasized that it had not engaged SES ESG Research for obtaining this ESG rating. The research firm independently prepared the assessment using data available in the public domain. This disclosure was made pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

SEBI Master Circular Compliance

The intimation aligns with the recent SEBI Master Circular no. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. This circular appears to have established new guidelines for companies regarding ESG rating disclosures to stock exchanges.

Corporate Communication

The formal intimation was signed by Trisha A, who serves as the Compliance Officer and Company Secretary of OneSource Specialty Pharma Limited. The disclosure was simultaneously sent to both BSE Limited and National Stock Exchange of India Limited, where the company's shares are listed under scrip code 544292 and symbol ONESOURCE respectively.

OneSource Specialty Pharma Limited has achieved a significant regulatory milestone with the Saudi Food and Drug Authority (SFDA) approval of its generic Ozempic (semaglutide) for the Saudi Arabian market. The approval enables the company to commercialise the diabetes therapy through an exclusive partnership with Hikma Pharmaceuticals PLC across the Middle East and North Africa (MENA) region.

Strategic Partnership Details

The exclusive agreement establishes a clear division of responsibilities between the two pharmaceutical companies:

Market Significance

The approval represents OneSource's strategic entry into Saudi Arabia, identified as one of the largest markets globally for GLP-1 therapies. The partnership positions both companies to capitalise on the rising demand for semaglutide while expanding access to affordable generic alternatives across the region.

Mr. Neeraj Sharma, CEO & MD of OneSource Specialty Pharma Limited, expressed enthusiasm about the development: "We are extremely excited to secure SFDA approval for semaglutide in Saudi Arabia, one of the largest GLP-1 market globally with significant long-term potential. We are confident that collaborating with Hikma, the largest pharmaceutical company in the MENA region by sales, will give us a strong platform to scale access to this important therapy across both private and institutional customers."

Company Capabilities

OneSource operates as a pure-play specialty pharmaceutical CDMO with comprehensive manufacturing capabilities:

Partnership Leverage

Hikma Pharmaceuticals brings substantial commercial expertise to the partnership, operating as the largest pharmaceutical company in MENA based on sales. The company maintains extensive commercial reach and institutional relationships across the region, providing the infrastructure necessary to scale access to semaglutide therapy.

The collaboration combines OneSource's manufacturing capabilities with Hikma's established market presence, creating a comprehensive approach to generic semaglutide distribution in the MENA region. This strategic alignment supports both companies' shared objective of increasing patient access to high-quality, affordable generic alternatives.

Source: